Wegovy tablets contain semaglutide, the same active ingredient used in the familiar injection, but taking the medicine by mouth changes more than the presence of a needle. The tablet has a daily routine, absorption conditions and evidence that need to be understood in their own right.
The UK Medicines and Healthcare products Regulatory Agency approved the tablet on 11 June 2026. Its weight-management indication is for adults with obesity, or overweight with at least one weight-related condition, alongside diet and physical activity. It remains a prescription medicine.
The daily routine is different
The UK product information describes a daily tablet after at least eight hours without food, swallowed whole with up to 120 mL of water. It specifies a wait of at least 30 minutes before food, drink or other oral medicines. These conditions affect absorption; they are part of the formulation’s use, rather than incidental packaging advice.
Removing an injection therefore does not remove the work of following a treatment routine. The practical comparison is between two different routines, rather than between treatment effort and no effort.
Nor can the number of milligrams on a tablet be read as a direct comparison with the number on an injection. The UK document notes greater variability in absorption with oral semaglutide. Any change between formulations belongs with the prescriber; a numerical comparison of package strengths is not a switching plan.
What the tablet trial measured
The product information reports OASIS 4, a 64-week randomized, placebo-controlled trial involving 307 adults. In its main analysis, average body-weight change was −13.6% with oral semaglutide and −2.2% with placebo. Participants also followed a reduced-calorie diet and increased physical activity.
Those figures describe groups in that trial. They are not an individual forecast, and the comparator was placebo, not injectable Wegovy. Comparing the tablet’s headline result with a percentage from a different injection trial would not establish which formulation works better for the same person.
The European Medicines Agency’s overview also distinguishes the formulations’ populations: tablets are intended for adults, while the injection has an adolescent indication under specified conditions. A shared brand name does not make every indication interchangeable.
A pill still has a medicine’s risks
The MHRA lists gastrointestinal effects, including nausea, vomiting, diarrhoea and constipation, among the common side effects. A tablet should not be understood as a version without semaglutide’s treatment risks. The full product information contains the warnings, interactions and restrictions that a short comparison cannot replace.
This is also why convenience and suitability are different questions. Someone may prefer avoiding needles, but that preference alone does not establish which formulation is appropriate, whether its administration conditions fit their circumstances, or how it interacts with other treatment.
Approval is one part of access
UK authorization establishes the permitted product use. It does not, by itself, establish NHS eligibility, a local pharmacy’s stock, the cost of a private prescription or availability in another country.
The useful change is an additional licensed formulation with its own evidence and routine. Whether it changes a particular person’s treatment is a separate prescribing decision—not something that can be settled by replacing “weekly injection” with “daily pill” in an otherwise unchanged comparison.